Bill Sibold is President and Chief Executive Officer of Madrigal Pharmaceuticals, Inc. (MDGL). The company reported total compensation of $19,206,341 for fiscal year 2025.
| Salary | $918,531 |
|---|---|
| Bonus | $0 |
| Stock awards | $12,297,850 |
| Option awards | $4,537,146 |
| Non-equity incentive plan | $1,438,814 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,000 |
| Total | $19,206,341 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Madrigal Pharmaceuticals, Inc. filed April 28, 2026, accession 0001308179-26-000352.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bill Sibold this page | President and Chief Executive Officer | $19,206,341 |
| David Soergel | Executive Vice President and Chief Medical Officer | $9,190,678 |
| Rebecca Taub | Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer | $6,868,016 |
| Mardi Dier | Executive Vice President and Chief Financial Officer | $6,085,089 |
| Carole Huntsman | Executive Vice President and Chief Commercial Officer | $5,441,736 |
| Shannon Kelley | Executive Vice President and Chief Legal Counsel | $5,179,352 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Madrigal Pharmaceuticals, Inc. compensation brief.
Bill Sibold's compensation sits inside Madrigal Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Madrigal Pharmaceuticals, Inc. (MDGL) compensation brief